Leerink Partners Office Conference Room

The Healthcare Investment Bank

Three decades of partnering with companies that are transforming the future of healthcare.

Who we are

Exclusively focused on healthcare, our specialized team offers a depth of expertise and an extensive network, positioning us as the preferred partner for healthcare companies and their investors. Our deep understanding of the complex healthcare industry drives clients to seek our trusted advice and investment solutions.

As of September 30, 2024

  • 1270

    +

    Transactions
Completed

  • $

    170

    B+

    Capital Raised

  • $

    65

    B+

    M&A Advisory

Leerink Partners- Runner with prosthetic leg; Investing in What Matters
Leerink Partners, The Healthcare Investment Bank, Background

How We’re Different

Leerink Partners -hologram x-ray of a torso projected on a desk

Solely Focused on Healthcare

We develop tailored strategies for each client based on decades of experience across biopharma, digital health, health tech, tools and diagnostics, healthcare services, and medical technology. With expertise spanning all key subsectors of healthcare, our team brings a wealth of knowledge to each transaction. Our senior bankers take pride in leading every step of the way, from deal origination to closing.

Biopharma

As long-standing leaders in the sector, we collaborate with innovators from growth stage biotechs to large-cap pharmaceuticals.

LEARN MORE

Digital Health & Health Technology

In this fast-growing segment, we work with companies using digital channels and new technologies to improve clinical outcomes, reduce costs and inform healthcare consumers.

LEARN MORE

Healthcare Services

We partner with the nation’s largest payers and providers, guiding them through financial, technological, and regulatory change.

LEARN MORE

Medical Technology

Our team brings years of technology experience to partner with MedTech clients to solve their strategic and capital markets needs.

LEARN MORE

Tools & Diagnostics

With decades of experience in diagnostics and tools, we work with leaders to drive advancements across the fast-growing sector.

LEARN MORE
Leerink Partners Biopharma Background Image

Recent Transactions

$150 Million
Joint Bookrunner
Follow-On
October 2024
$75 Million
Joint Bookrunner
Initial Public Offering
October 2024
UNDISCLOSED
Exclusive Financial Advisor
Acquisition of Global Rights to BRM-1420 from Bridge Medicines
October 2024
Crinetics Logo
$500 Million
Joint Bookrunner
Follow-On
October 2024
View all Transactions
Banner desktop

Partner With Us

Let us help you achieve your strategic,
capital markets, and investment objectives

Contact Us

Our experienced team is happy to assist you. Please complete the form below and we’ll be in touch as soon as possible. *” indicates required fields

This field is for validation purposes and should be left unchanged.